These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Rare dual-genotype IDH mutant glioma: Review of previously reported cases and two new cases of true "oligoastrocytoma". Sutherland I; DeWitt J; Thomas A Neuropathology; 2024 Oct; 44(5):401-407. PubMed ID: 38581197 [TBL] [Abstract][Full Text] [Related]
3. Radiographic growth rate as a predictor of aggressiveness of diffuse gliomas without 1p19q codeletion. Leclerc A; Roux A; Elia A; Peeters S; Aboubakr O; Bedioui A; Planet M; Benzakoun J; Simboli GA; Tauziede-Espariat A; Moiraghi A; Varlet P; Chrétien F; Oppenheim C; Zanello M; Pallud J Neurosurg Focus; 2024 Feb; 56(2):E4. PubMed ID: 38301236 [TBL] [Abstract][Full Text] [Related]
4. Molecular genetics of adult grade II gliomas: towards a comprehensive tumor classification system. Figarella-Branger D; Bouvier C; de Paula AM; Mokhtari K; Colin C; Loundou A; Chinot O; Metellus P J Neurooncol; 2012 Nov; 110(2):205-13. PubMed ID: 22890969 [TBL] [Abstract][Full Text] [Related]
5. Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas. Zhou H; Chang K; Bai HX; Xiao B; Su C; Bi WL; Zhang PJ; Senders JT; Vallières M; Kavouridis VK; Boaro A; Arnaout O; Yang L; Huang RY J Neurooncol; 2019 Apr; 142(2):299-307. PubMed ID: 30661193 [TBL] [Abstract][Full Text] [Related]
6. IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas. Darlix A; Deverdun J; Menjot de Champfleur N; Castan F; Zouaoui S; Rigau V; Fabbro M; Yordanova Y; Le Bars E; Bauchet L; Gozé C; Duffau H J Neurooncol; 2017 May; 133(1):37-45. PubMed ID: 28434111 [TBL] [Abstract][Full Text] [Related]
7. The clinical significance of the T2-FLAIR mismatch sign in grade II and III gliomas: a population-based study. Corell A; Ferreyra Vega S; Hoefling N; Carstam L; Smits A; Olsson Bontell T; Björkman-Burtscher IM; Carén H; Jakola AS BMC Cancer; 2020 May; 20(1):450. PubMed ID: 32434559 [TBL] [Abstract][Full Text] [Related]
8. Mitotic count is prognostic in IDH mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trial 26053 (CATNON) and EORTC trial 22033-26033. Kros JM; Rushing E; Uwimana AL; Hernández-Laín A; Michotte A; Al-Hussaini M; Bielle F; Mawrin C; Marucci G; Tesileanu CMS; Stupp R; Baumert B; van den Bent M; French PJ; Gorlia T Neuro Oncol; 2023 Aug; 25(8):1443-1449. PubMed ID: 36571817 [TBL] [Abstract][Full Text] [Related]
9. T Kinoshita M; Uchikoshi M; Sakai M; Kanemura Y; Kishima H; Nakanishi K Magn Reson Med Sci; 2021 Mar; 20(1):119-123. PubMed ID: 32101817 [TBL] [Abstract][Full Text] [Related]
10. Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas. Macaulay RJ Cancer Control; 2015 Apr; 22(2):200-5. PubMed ID: 26068765 [TBL] [Abstract][Full Text] [Related]
11. Molecular subtypes of glioma identified by genome-wide methylation profiling. Kloosterhof NK; de Rooi JJ; Kros M; Eilers PH; Sillevis Smitt PA; van den Bent MJ; French PJ Genes Chromosomes Cancer; 2013 Jul; 52(7):665-74. PubMed ID: 23629961 [TBL] [Abstract][Full Text] [Related]
12. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Reuss DE; Sahm F; Schrimpf D; Wiestler B; Capper D; Koelsche C; Schweizer L; Korshunov A; Jones DT; Hovestadt V; Mittelbronn M; Schittenhelm J; Herold-Mende C; Unterberg A; Platten M; Weller M; Wick W; Pfister SM; von Deimling A Acta Neuropathol; 2015 Jan; 129(1):133-46. PubMed ID: 25427834 [TBL] [Abstract][Full Text] [Related]
13. Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas. Ducray F; Mokhtari K; Crinière E; Idbaih A; Marie Y; Dehais C; Paris S; Carpentier C; Dieme MJ; Adam C; Hoang-Xuan K; Duyckaerts C; Delattre JY; Sanson M Eur J Cancer; 2011 Mar; 47(5):802-8. PubMed ID: 21194923 [TBL] [Abstract][Full Text] [Related]
14. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286 [TBL] [Abstract][Full Text] [Related]
16. [Mutation of isocitrate dehydrogenase gene in Chinese patients with glioma]. Pan Y; Qi XL; Wang LM; Dong RF; Zhang M; Zheng DF; Chang Q; Zhong YF Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):292-8. PubMed ID: 24004584 [TBL] [Abstract][Full Text] [Related]
17. Oligodendroglial tumors with marked desmoplasia: clinicopathologic and molecular features of 7 cases. Jentoft M; Giannini C; Rossi S; Mota R; Jenkins RB; Rodriguez FJ Am J Surg Pathol; 2011 Jun; 35(6):845-52. PubMed ID: 21552114 [TBL] [Abstract][Full Text] [Related]
18. Estimation of the occurrence rates of Cho U; Yang SH; Yoo C J Int Med Res; 2021 Jun; 49(6):3000605211019258. PubMed ID: 34162262 [TBL] [Abstract][Full Text] [Related]
19. Conventional MR-based Preoperative Nomograms for Prediction of IDH/1p19q Subtype in Low-Grade Glioma. Liu Z; Zhang T; Jiang H; Xu W; Zhang J Acad Radiol; 2019 Aug; 26(8):1062-1070. PubMed ID: 30393056 [TBL] [Abstract][Full Text] [Related]
20. Histomolecular classification of adult diffuse gliomas: the diagnostic value of immunohistochemical markers. Figarella-Branger D; Maues de Paula A; Colin C; Bouvier C Rev Neurol (Paris); 2011 Oct; 167(10):683-90. PubMed ID: 21889777 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]